Skip to main content

Farrell Michael J.'s Form 4 filing

Resmed Inc (RMD) · filed Jun 10, 2024

Accession no.
0001127602-24-018325
Filed
Jun 10, 2024
Trade date
Jun 7, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.11M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Farrell Michael J.CIK 0001485164Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 7, 2024ResMed Common StockMOption exerciseAcquired+14,683$84.98+$1,247,761.34455,482Direct
Jun 7, 2024ResMed Common StockSSaleDisposed−14,683$211.66F2−$3,107,803.78440,799Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 7, 2024ResMed Common StockMOption exerciseDisposed−14,683$0.00$073,415Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $210.58 - $213.86. The price reported above reflects the weighted average sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)